Novartis shareholder pushes for board overhaul amid trial failures

A significant shareholder in Novartis has publicly demanded a restructuring of the company's board following a series of unsuccessful clinical trials, signalling growing investor concern over the firm's drug development pipeline.

The shareholder, while acknowledging that Chief Executive Officer Vas Narasimhan has performed well in his role, believes changes to the board's composition are necessary to address the recent disappointments. The call for action reflects broader frustrations among investors about the frequency and impact of the trial setbacks on the company's future prospects.

Novartis, headquartered in Basel, is one of the world's largest pharmaceutical manufacturers and a significant player in global healthcare markets. The company's performance is closely watched by investors across Asia-Pacific, where it maintains substantial operations and market presence.

The shareholder's intervention underscores the delicate balance pharmaceutical companies must strike between maintaining leadership continuity and demonstrating responsiveness to investor concerns. The company has not yet publicly responded to the call for board changes.

The situation highlights ongoing challenges facing major drug developers as they navigate increasingly rigorous regulatory requirements and the high costs associated with bringing new medicines to market.